{"id":66970,"date":"2026-06-01T15:05:50","date_gmt":"2026-06-01T07:05:50","guid":{"rendered":"https:\/\/flcube.com\/?p=66970"},"modified":"2026-06-01T15:05:51","modified_gmt":"2026-06-01T07:05:51","slug":"lynk-pharmaceuticals-advances-pan-jak-inhibitor-lnk01004-into-phase-ii-for-vitiligo-and-hand-eczema-with-skin-restricted-design","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66970","title":{"rendered":"Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Lynk Pharmaceuticals Co., Ltd.<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted clearance to initiate a <strong>Phase II clinical study<\/strong> of <strong>LNK01004 ointment<\/strong> for the treatment of <strong>vitiligo<\/strong> and <strong>chronic hand eczema<\/strong>. The <strong>third-generation soft pan-JAK inhibitor<\/strong> features an innovative <strong>skin-restricted distribution profile<\/strong> with <strong>low systemic exposure<\/strong>, designed to optimize the balance between therapeutic efficacy and safety for long-term dermatological use. The compound builds on positive Phase II results in atopic dermatitis, demonstrating favorable efficacy and safety in inflammatory skin conditions.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-details\" class=\"wp-block-heading\">Clinical Development Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Lynk Pharmaceuticals Co., Ltd.<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>LNK01004 ointment<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Third-generation soft pan-JAK inhibitor<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase II clinical trial approved<\/td><\/tr><tr><td><strong>Target Indications<\/strong><\/td><td>Vitiligo and chronic hand eczema<\/td><\/tr><tr><td><strong>Previous Clinical Data<\/strong><\/td><td>Positive Phase II results in atopic dermatitis<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>01 Jun 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-innovative-design\" class=\"wp-block-heading\">Drug Profile &amp; Innovative Design<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: <strong>Pan-JAK inhibition<\/strong> targeting multiple Janus kinase pathways involved in inflammatory skin diseases<\/li>\n\n\n\n<li><strong>Delivery System<\/strong>: <strong>Topical ointment<\/strong> formulation with optimized transdermal permeability<\/li>\n\n\n\n<li><strong>Systemic Safety<\/strong>: Engineered for <strong>rapid metabolism and clearance<\/strong> upon entering bloodstream, resulting in <strong>short plasma half-life<\/strong> and <strong>extremely low systemic exposure<\/strong><\/li>\n\n\n\n<li><strong>Tissue Selectivity<\/strong>: <strong>Skin-restricted distribution<\/strong> ensures primary drug exposure remains localized to target tissue<\/li>\n\n\n\n<li><strong>Long-term Use<\/strong>: Design enables safe chronic administration without systemic JAK inhibitor safety concerns<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-preclinical-amp-clinical-evidence\" class=\"wp-block-heading\">Preclinical &amp; Clinical Evidence<\/h2>\n\n\n\n<h3 id=\"h-preclinical-studies\" class=\"wp-block-heading\">Preclinical Studies<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Skin-restricted characteristics<\/strong>: Demonstrated distinct localization to skin tissue with minimal systemic distribution<\/li>\n\n\n\n<li><strong>Anti-inflammatory efficacy<\/strong>: Strong activity in multiple inflammatory skin disease models<\/li>\n\n\n\n<li><strong>Safety profile<\/strong>: Favorable tolerability with no significant systemic toxicity observed<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-experience\" class=\"wp-block-heading\">Clinical Experience<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Atopic Dermatitis Phase II<\/strong>: Showed <strong>favorable efficacy and safety<\/strong> in completed trial<\/li>\n\n\n\n<li><strong>Dosing Flexibility<\/strong>: Suitable for once or twice daily application based on disease severity<\/li>\n\n\n\n<li><strong>Patient Compliance<\/strong>: Ointment formulation enhances adherence compared to liquid or gel alternatives<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-market-implications\" class=\"wp-block-heading\">Strategic Market Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The expansion into <strong>vitiligo<\/strong> and <strong>chronic hand eczema<\/strong> addresses significant unmet needs in China&#8217;s dermatology market:<\/p>\n\n\n\n<h3 id=\"h-vitiligo-market\" class=\"wp-block-heading\">Vitiligo Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population<\/strong>: Estimated <strong>3\u20135 million vitiligo patients<\/strong> in China<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: Limited effective therapies; current options include phototherapy and topical corticosteroids with variable efficacy<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong>: Premium pricing potential for first effective JAK inhibitor specifically developed for vitiligo<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-chronic-hand-eczema-market\" class=\"wp-block-heading\">Chronic Hand Eczema Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: Affects approximately <strong>10% of working-age population<\/strong> in industrialized countries<\/li>\n\n\n\n<li><strong>Economic Impact<\/strong>: Significant occupational disability and healthcare costs<\/li>\n\n\n\n<li><strong>Therapeutic Need<\/strong>: Current treatments often inadequate; JAK inhibitors represent novel mechanism of action<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;This Phase II approval represents a strategic expansion of LNK01004&#8217;s clinical program into two important inflammatory skin conditions with substantial unmet medical needs,&#8221; said Dr. Chen Wei, Chief Executive Officer of Lynk Pharmaceuticals. &#8220;Our skin-restricted design philosophy ensures that patients can benefit from potent pan-JAK inhibition without the systemic safety concerns that have limited other JAK inhibitors in chronic dermatological applications.&#8221;<\/p>\n\n\n\n<h2 id=\"h-competitive-differentiation-amp-commercial-outlook\" class=\"wp-block-heading\">Competitive Differentiation &amp; Commercial Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Lynk&#8217;s approach offers distinct advantages in the evolving JAK inhibitor landscape:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Safety Leadership<\/strong>: Skin-restricted distribution addresses regulatory concerns about systemic JAK inhibitor safety<\/li>\n\n\n\n<li><strong>Broad Applicability<\/strong>: Single molecule effective across multiple inflammatory skin diseases<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Benefits from established JAK inhibitor development precedents while differentiating on safety<\/li>\n\n\n\n<li><strong>Market Timing<\/strong>: Enters market as dermatology-focused JAK inhibitors gain acceptance following recent approvals<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts estimate the combined Chinese market for vitiligo and chronic hand eczema treatments could reach <strong>\u00a53\u20135 billion ($420\u2013700 million) annually<\/strong>, with LNK01004 well-positioned to capture significant share given its innovative safety profile and demonstrated clinical efficacy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and market opportunities for LNK01004. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lynk Pharmaceuticals Co., Ltd. announced that China&#8217;s National Medical Products Administration (NMPA) has granted clearance&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,62,1351],"class_list":["post-66970","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-approval-initiation","tag-lynk-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lynk Pharmaceuticals Co., Ltd. announced that China&#039;s National Medical Products Administration (NMPA) has granted clearance to initiate a Phase II clinical study of LNK01004 ointment for the treatment of vitiligo and chronic hand eczema. The third-generation soft pan-JAK inhibitor features an innovative skin-restricted distribution profile with low systemic exposure, designed to optimize the balance between therapeutic efficacy and safety for long-term dermatological use. The compound builds on positive Phase II results in atopic dermatitis, demonstrating favorable efficacy and safety in inflammatory skin conditions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66970\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design\" \/>\n<meta property=\"og:description\" content=\"Lynk Pharmaceuticals Co., Ltd. announced that China&#039;s National Medical Products Administration (NMPA) has granted clearance to initiate a Phase II clinical study of LNK01004 ointment for the treatment of vitiligo and chronic hand eczema. The third-generation soft pan-JAK inhibitor features an innovative skin-restricted distribution profile with low systemic exposure, designed to optimize the balance between therapeutic efficacy and safety for long-term dermatological use. The compound builds on positive Phase II results in atopic dermatitis, demonstrating favorable efficacy and safety in inflammatory skin conditions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66970\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T07:05:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T07:05:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66970#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66970\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design\",\"datePublished\":\"2026-06-01T07:05:50+00:00\",\"dateModified\":\"2026-06-01T07:05:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66970\"},\"wordCount\":592,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Clinical trial approval \\\/ initiation\",\"Lynk Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66970#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66970\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66970\",\"name\":\"Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-01T07:05:50+00:00\",\"dateModified\":\"2026-06-01T07:05:51+00:00\",\"description\":\"Lynk Pharmaceuticals Co., Ltd. announced that China's National Medical Products Administration (NMPA) has granted clearance to initiate a Phase II clinical study of LNK01004 ointment for the treatment of vitiligo and chronic hand eczema. The third-generation soft pan-JAK inhibitor features an innovative skin-restricted distribution profile with low systemic exposure, designed to optimize the balance between therapeutic efficacy and safety for long-term dermatological use. The compound builds on positive Phase II results in atopic dermatitis, demonstrating favorable efficacy and safety in inflammatory skin conditions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66970#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66970\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66970#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design - Insight, China&#039;s Pharmaceutical Industry","description":"Lynk Pharmaceuticals Co., Ltd. announced that China's National Medical Products Administration (NMPA) has granted clearance to initiate a Phase II clinical study of LNK01004 ointment for the treatment of vitiligo and chronic hand eczema. The third-generation soft pan-JAK inhibitor features an innovative skin-restricted distribution profile with low systemic exposure, designed to optimize the balance between therapeutic efficacy and safety for long-term dermatological use. The compound builds on positive Phase II results in atopic dermatitis, demonstrating favorable efficacy and safety in inflammatory skin conditions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66970","og_locale":"en_US","og_type":"article","og_title":"Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design","og_description":"Lynk Pharmaceuticals Co., Ltd. announced that China's National Medical Products Administration (NMPA) has granted clearance to initiate a Phase II clinical study of LNK01004 ointment for the treatment of vitiligo and chronic hand eczema. The third-generation soft pan-JAK inhibitor features an innovative skin-restricted distribution profile with low systemic exposure, designed to optimize the balance between therapeutic efficacy and safety for long-term dermatological use. The compound builds on positive Phase II results in atopic dermatitis, demonstrating favorable efficacy and safety in inflammatory skin conditions.","og_url":"https:\/\/flcube.com\/?p=66970","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-01T07:05:50+00:00","article_modified_time":"2026-06-01T07:05:51+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66970#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66970"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design","datePublished":"2026-06-01T07:05:50+00:00","dateModified":"2026-06-01T07:05:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66970"},"wordCount":592,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Clinical trial approval \/ initiation","Lynk Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66970#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66970","url":"https:\/\/flcube.com\/?p=66970","name":"Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-01T07:05:50+00:00","dateModified":"2026-06-01T07:05:51+00:00","description":"Lynk Pharmaceuticals Co., Ltd. announced that China's National Medical Products Administration (NMPA) has granted clearance to initiate a Phase II clinical study of LNK01004 ointment for the treatment of vitiligo and chronic hand eczema. The third-generation soft pan-JAK inhibitor features an innovative skin-restricted distribution profile with low systemic exposure, designed to optimize the balance between therapeutic efficacy and safety for long-term dermatological use. The compound builds on positive Phase II results in atopic dermatitis, demonstrating favorable efficacy and safety in inflammatory skin conditions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66970#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66970"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66970#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66970","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66970"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66970\/revisions"}],"predecessor-version":[{"id":66971,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66970\/revisions\/66971"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66970"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66970"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66970"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}